Please use this identifier to cite or link to this item:
Title: Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
Austin Authors: Schnurr, Max;Chen, Qiyuan;Shin, Amanda;Chen, Weisan;Toy, Tracey;Jenderek, Corinna;Green, Simon;Miloradovic, Lena;Drane, Debbie;Davis, Ian D;Villadangos, Jose;Shortman, Ken;Maraskovsky, Eugene;Cebon, Jonathan S 
Affiliation: Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 16-Nov-2004
Publication information: Blood 2004; 105(6): 2465-72
Abstract: Dendritic cells (DCs) are being evaluated for cancer immunotherapy due to their unique ability to induce tumor-directed T-cell responses. Here we report that the type of human DC, the mode of activation, and the strategy for delivery of antigen are 3 critical factors for efficient stimulation of tumor-specific CD8+ and CD4+ T cells. Only CD1c+ blood DCs and monocyte-derived DCs (MoDCs) were capable of presenting epitopes of the full-length tumor antigen NY-ESO-1 on both major histocompatibility complex (MHC) class I (cross-presentation) and MHC II, whereas plasmacytoid DCs were limited to MHC II presentation. Cross-presentation was inefficient for soluble protein, but highly efficient for antigen-antibody immune complexes (NY-ESO-1/IC) and for protein formulated with ISCOMATRIX adjuvant (NY-ESO-1/IMX). DC activation with CD40L further enhanced cross-presentation efficiency. The mode of antigen delivery was found to be a determining factor for cytosolic proteolysis by DCs. Immune complexes (ICs) targeted a slow, proteasome-dependent cross-presentation pathway, whereas ISCOMATRIX (IMX) targeted a fast, proteasome-independent pathway. Both cross-presentation pathways resulted in a long-lived, T-cell stimulatory capacity, which was maintained for several days longer than for DCs pulsed with peptide. This may provide DCs with ample opportunities for sensitizing tumor-specific T cells against a broad array of tumor antigen epitopes in lymph nodes.
Gov't Doc #: 15546948
DOI: 10.1182/blood-2004-08-3105
Type: Journal Article
Subjects: Adjuvants, Immunologic.administration & dosage
Antigen Presentation.drug effects.immunology
Antigen-Antibody Complex.immunology
Antigens, Neoplasm.administration & dosage.immunology
CD4-Positive T-Lymphocytes.immunology.pathology
CD8-Positive T-Lymphocytes.immunology.pathology
Cancer Vaccines.administration & dosage.immunology
Cells, Cultured
Cholesterol.administration & dosage.immunology
Dendritic Cells.immunology.pathology
Drug Combinations
Epitopes, T-Lymphocyte.immunology
Histocompatibility Antigens Class I.immunology
Histocompatibility Antigens Class II.immunology
Lymph Nodes.immunology.pathology
Membrane Proteins.administration & dosage.immunology
Phospholipids.administration & dosage.immunology
Plasma Cells.immunology.pathology
Proteasome Endopeptidase Complex.immunology
Saponins.administration & dosage.immunology
Appears in Collections:Journal articles

Files in This Item:
File Description SizeFormat 
15546948.pdf366.26 kBAdobe PDFThumbnail
Show full item record


checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.